Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

FDA sets January decision date for Xalkori in ALK-positive lymphoma

FDA submission is based on results from ADVL0912 and A8081013 studies

Using Artificial Intelligence to Transform Pharma

Dr. Andree Bates, Founder & CEO of Eularis, discusses how Eularis helps healthcare teams utilize AI and “Future Tech” to solve their biggest commercial challenges and deliver measurable growth. Among many...

Impetus Digital

Session 4: Systems Innovation Insight and Thinking

Impetus Digital

Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights

Aaron Leibtag, CEO & Co-Founder of Pentavere Research Group, discusses his transition from being an Organizational Transformation Leader to co-founding a startup focused on healthcare technology. We also dive into how...

Impetus Digital

- PMLiVE

Surviving cancer: a new era for patients

Now more than ever, a shift in perspective is needed

- PMLiVE

Stop that!

You might think better if you were less of a scientist

- PMLiVE

EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease

Gene therapy has been given a PRIME designation

Andrew Smith

Crisis? No problem!

Issues planning & management for pharma spokespeople, by Andrew Smith

Havas Life London

- PMLiVE

UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus

UK human ‘challenge trial’ programme would be a world first

- PMLiVE

Keytruda doubles five-year survival rate in NSCLC

Merck reveals long-term efficacy data for blockbuster immunotherapy

- PMLiVE

Could formulary intelligence be your brand differentiator?

Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch

- PMLiVE

Relief Therapeutics seeks US emergency approval for COVID-19 drug

If granted, EUA would give approval for use in severely ill patients with no other treatment options

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links